Lanreotide
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Lanreotide and local guidelines before prescribing.
Somatostatin analogue
Mechanism
Long-acting somatostatin analogue.
Uses
Acromegaly, neuroendocrine tumours.
Dosing
- Lanreotide Acromegaly | 60–120 mg deep SC every 4 weeks.
Endocrinology: Pituitary Disease - Drugs: Octreotide LAR (e.g. 30 mg IM every 4 weeks), lanreotide (120 mg deep SC every 4 weeks), or short-acting SC octreotide.
Endocrinology: NETS and Hypoglycaemia - Octreotide / lanreotide NETs | Octreotide LAR 30 mg IM, or lanreotide 120 mg deep SC, 4-weekly. Symptom and tumour control. Gallstones.
Endocrinology: NETS and Hypoglycaemia
Side effects
Diarrhoea, gallstones, injection-site reactions, bradycardia.
Interactions
Ciclosporin levels fall.
Contraindications and cautions
Hypersensitivity
Monitoring
IGF-1, glucose
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Reduce dose in renal and hepatic impairment
Overdose and reversal
Supportive
Special advice
Monitor glucose and gallbladder.
More from the textbook: uses, cautions and other points
- Somatostatin analogues - octreotide LAR or lanreotide, monthly injections. They reduce GH and often shrink the tumour. Side effects: gallstones , GI upset, hyperglycaemia.
Endocrinology: Pituitary Disease - Octreotide / lanreotide | Acromegaly, NETs; gallstones.
Endocrine: Anatomy Physiology and Pharmacology - Somatostatin analogues - octreotide or lanreotide - control symptoms in most patients and slow tumour growth.
Endocrinology: NETS and Hypoglycaemia
Where it is discussed in the book
- Endocrine: Anatomy Physiology and Pharmacology (1 mention)
- Endocrinology: Pituitary Disease (2 mentions)
- Endocrinology: NETS and Hypoglycaemia (3 mentions)